Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 84

1.

Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer.

Oehme F, Krahl S, Gyorffy B, Muessle B, Rao V, Greif H, Ziegler N, Lin K, Thepkaysone ML, Polster H, Tonn T, Schneider M, Weitz J, Baenke F, Kahlert C.

RNA Biol. 2019 Oct;16(10):1339-1345. doi: 10.1080/15476286.2019.1637697. Epub 2019 Jul 7.

PMID:
31251124
2.

Colony Formation: An Assay of Hematopoietic Progenitor Cells.

Kronstein-Wiedemann R, Tonn T.

Methods Mol Biol. 2019;2017:29-40. doi: 10.1007/978-1-4939-9574-5_3.

PMID:
31197766
3.

Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes.

Rahbari M, Pecqueux M, Aust D, Stephan H, Tiebel O, Chatzigeorgiou A, Tonn T, Baenke F, Rao V, Ziegler N, Greif H, Lin K, Weitz J, Rahbari NN, Kahlert C.

J Clin Med. 2019 May 16;8(5). pii: E696. doi: 10.3390/jcm8050696.

4.

Human immunodeficiency virus 1 dual-target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden-Württemberg-Hessen.

Hourfar K, Eberle J, Müller M, Micha Nübling C, Chudy M, Kress J, Gürtler L, Mayr-Wohlfart U, Schrezenmeier H, Hellmann I, Luhm J, Kraas S, Ringwald J, Gubbe K, Frank K, Karl A, Tonn T, Jaeger M, Sireis W, Seifried E, Schmidt M.

Transfusion. 2018 Dec;58(12):2886-2893. doi: 10.1111/trf.14919. Epub 2018 Oct 16.

PMID:
30325043
5.

Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.

Zhou D, Xu L, Huang W, Tonn T.

Molecules. 2018 May 31;23(6). pii: E1326. doi: 10.3390/molecules23061326. Review.

6.

PRAME peptide-specific CD8+ T cells represent the predominant response against leukemia-associated antigens in healthy individuals.

Matko S, Manderla J, Bonsack M, Schmitz M, Bornhauser M, Tonn T, Odendahl M.

Eur J Immunol. 2018 Aug;48(8):1400-1411. doi: 10.1002/eji.201747399. Epub 2018 Jul 8.

7.

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.

Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, Wels WS, Tonn T.

Cancer Immunol Immunother. 2018 Jan;67(1):25-38. doi: 10.1007/s00262-017-2055-2. Epub 2017 Sep 6.

PMID:
28879551
8.

Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.

Mitroulis I, Chen LS, Singh RP, Kourtzelis I, Economopoulou M, Kajikawa T, Troullinaki M, Ziogas A, Ruppova K, Hosur K, Maekawa T, Wang B, Subramanian P, Tonn T, Verginis P, von Bonin M, Wobus M, Bornhäuser M, Grinenko T, Di Scala M, Hidalgo A, Wielockx B, Hajishengallis G, Chavakis T.

J Clin Invest. 2017 Oct 2;127(10):3624-3639. doi: 10.1172/JCI92571. Epub 2017 Aug 28.

9.

Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells.

Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stölzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M.

Haematologica. 2017 Nov;102(11):e460-e464. doi: 10.3324/haematol.2017.167312. Epub 2017 Aug 24. No abstract available.

10.

EV-3, an endogenous human erythropoietin isoform with distinct functional relevance.

Bonnas C, Wüstefeld L, Winkler D, Kronstein-Wiedemann R, Dere E, Specht K, Boxberg M, Tonn T, Ehrenreich H, Stadler H, Sillaber I.

Sci Rep. 2017 Jun 16;7(1):3684. doi: 10.1038/s41598-017-03167-0.

11.

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.

Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS.

Front Immunol. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533. eCollection 2017.

12.

Detection of the relatively slow-growing Propionibacterium acnes in seven matrices of blood components and advanced therapeutical medicinal products.

Arlt N, Rothe R, Juretzek T, Peltroche H, Tonn T, Moog R.

Transfus Apher Sci. 2017 Jun;56(3):461-465. doi: 10.1016/j.transci.2017.05.001. Epub 2017 May 19.

PMID:
28571932
13.

Enumeration of WT1-specific CD8+ T cells for clinical application using an MHC Streptamer based no-wash single-platform flow-cytometric assay.

Matko S, Teichert M, Tunger A, Schmitz M, Bornhauser M, Tonn T, Odendahl M.

Cytometry A. 2017 Oct;91(10):1001-1008. doi: 10.1002/cyto.a.23146. Epub 2017 May 25.

14.

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.

Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22.

PMID:
27887866
15.

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology.

Tunger A, Wehner R, von Bonin M, Kühn D, Heidenreich F, Matko S, Nauerth M, Rücker-Braun E, Dietz S, Link CS, Eugster A, Odendahl M, Busch DH, Tonn T, Bonifacio E, Germeroth L, Schetelig J, Bachmann MP, Bornhäuser M, Schmitz M.

Leuk Lymphoma. 2017 May;58(5):1246-1249. doi: 10.1080/10428194.2016.1233538. Epub 2016 Nov 16. No abstract available.

PMID:
27852136
16.

Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice.

Rahmig S, Kronstein-Wiedemann R, Fohgrub J, Kronstein N, Nevmerzhitskaya A, Bornhäuser M, Gassmann M, Platz A, Ordemann R, Tonn T, Waskow C.

Stem Cell Reports. 2016 Oct 11;7(4):591-601. doi: 10.1016/j.stemcr.2016.08.005. Epub 2016 Sep 8.

17.

Natural Killer Cells for Therapy of Leukemia.

Suck G, Linn YC, Tonn T.

Transfus Med Hemother. 2016 Mar;43(2):89-95. doi: 10.1159/000445325. Epub 2016 Mar 22. Review.

18.

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T.

J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23.

19.

Selection and expansion of natural killer cells for NK cell-based immunotherapy.

Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C.

Cancer Immunol Immunother. 2016 Apr;65(4):477-84. doi: 10.1007/s00262-016-1792-y. Epub 2016 Jan 25. Review.

20.

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O'Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B.

J Extracell Vesicles. 2015 Dec 31;4:30087. doi: 10.3402/jev.v4.30087. eCollection 2015.

Supplemental Content

Loading ...
Support Center